{"id":9078,"date":"2023-11-13T13:15:51","date_gmt":"2023-11-13T13:15:51","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=9078"},"modified":"2025-05-16T15:46:04","modified_gmt":"2025-05-16T15:46:04","slug":"explore-the-limitless-potential-of-il-18","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/explore-the-limitless-potential-of-il-18\/","title":{"rendered":"Explore the Limitless Potential of IL-18"},"content":{"rendered":"\n

IL-18, also known as the IFN gamma-inducing factor, is a proinflammatory cytokine and a member of the IL-1 family. Initially, it is produced as an inactive pro-form and then secreted after maturation by caspase-1. IL-18 binds to the IL-18 receptor \u03b1 (IL-18R\u03b1) expressed on the surface of various cells, such as Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts, adrenal cortex cells, and murine diencephalon, leading to inflammation. IL-18 also acts on T helper type-1 (Th1) cells and, when combined with IL-12, strongly induces them to produce IFN-\u03b3. IL-18 has pleiotropic effects, including enhancing the production of IFN-\u03b3 and GM-CSF in peripheral blood mononuclear cells and the production of Th1 cytokines IL-2, GM-CSF, and IFN-\u03b3 in T cells. It also enhances Fas ligand expression by Th1 cells. As a result, researchers are harnessing these regulatory processes for anti-tumour immune responses, as IL-18 enhances anti-tumour immunity in various cancer types. The potent activity of IL-18 in tumour models has underscored the significant potential of the IL-18 pathway as a target for tumour immunotherapy.<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Researchers take advantage of MBL International’s recombinant IL-18 to activate varying cells like peripheral blood cells, macrophages, NK cells and T cells to identify targets.<\/p>\n\n\n\n

For ex vivo studies, MBLI provides formulation without BSA. In addition, they offer other IL-18 products and are a trusted leader in IL-18 research worldwide. <\/p>\n\n\n\n

Product Code<\/strong><\/strong><\/td>Product Name <\/strong><\/strong><\/td>Size<\/strong><\/strong><\/td><\/tr>
B004-2<\/a><\/td>Recombinant Mouse IL-18 (Without BSA)<\/td>200 \u03bcg<\/td><\/tr>
B004-5<\/a><\/td>Recombinant Mouse IL-18 (without BSA)<\/td>25 \u03bcg<\/td><\/tr>
B003-5<\/a><\/td>Recombinant Human IL-18 (without BSA)<\/td>25 \u03bcg<\/td><\/tr>
B003-2<\/a><\/td>Recombinant IL-18 (without BSA)<\/td>200 \u03bcg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

REFERENCES:<\/p>\n\n\n\n

    \n
  1. Ohya, Takashi, et al. \u201cImpaired Interleukin\u201018 Signaling in Natural Killer Cells from Patients with Systemic Juvenile Idiopathic Arthritis.\u201d ACR Open Rheumatology<\/em>, vol. 4, no. 6, 2022, pp. 503\u2013510., doi:10.1002\/acr2.11426.<\/li>\n\n\n\n
  2. Wang, Zhen, et al. \u201cInterleukin-37 Promotes Colitis-Associated Carcinogenesis via SIGIRR-Mediated Cytotoxic T Cells Dysfunction.\u201d Signal Transduction and Targeted Therapy, vol. 7, no. 1, 2022, doi:10.1038\/s41392-021-00820-z.<\/li>\n\n\n\n
  3. Tsutsuki, Hiroyasu, et al. \u201cSubtilase Cytotoxin from Shiga-Toxigenic Escherichia Coli Impairs the Inflammasome and Exacerbates Enteropathogenic Bacterial Infection.\u201d IScience, vol. 25, no. 4, 2022, p. 104050., doi:10.1016\/j.isci.2022.104050.<\/li>\n\n\n\n
  4. Stone, Deborah L., et al. \u201cExcess Serum Interleukin\u201018 Distinguishes Patients with Pathogenic Mutations in pstpip1 .\u201d Arthritis &amp; Rheumatology, vol. 74, no. 2, 2022, pp. 353\u2013357., doi:10.1002\/art.41976.<\/li>\n<\/ol>\n\n\n\n
    \n\n\n\n

    Information provided by MBL.<\/p>\n\n\n\n

    Caltag Medsystems <\/a>is the distributor of MBL <\/a>products in the UK and Ireland. If you have any questions about these products, please contact us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Researchers take advantage of MBL International’s recombinant IL-18 to activate varying cells like peripheral blood cells, macrophages, NK cells and T cells to identify targets.<\/p>\n","protected":false},"author":13,"featured_media":9123,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,12,1],"tags":[7,693,67],"class_list":["post-9078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cell-signalling","category-general-information","tag-cancer","tag-il-18","tag-mbl-international"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/9078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=9078"}],"version-history":[{"count":5,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/9078\/revisions"}],"predecessor-version":[{"id":12266,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/9078\/revisions\/12266"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/9123"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=9078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=9078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=9078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}